This funding represents the company’s first debt and security raise. Since the company’s first raise in 2015, all funding to date has been equity only, totaling more than $86 million, according to SEC filings.
Read More
An interim CEO and other executive changes have been made at Durham based biopharma startup Aerami Therapeutics in the wake of the death of CEO Lisa Yanez.
Read More
“We and everyone who knew Lisa Yañez have suffered a major loss with her passing. Lisa was a passionate, authentic leader who worked shoulder to shoulder with her colleagues, always focused on bringing solutions to help people live longer and better lives,” says Anne Whitaker, executive chairwoman of the company’s Board of Directors.
Read More
Lisa Yanez, the chief operating officer at Aerami Therapeutics, will take over as the CEO on Jan. 1. Here’s what’s happening,.
Read More
A few months after mutually agreeing to terminate a deal with a special purpose acquisition company, Aerami Therapeutics has brought on a COO.
Read More
Aerami Therapeutics will combine with a special purpose acquisition company, then trade as a public company.
Read More
Aerami Therapeutics has raised more than $22 million from more than 200 investors.
Read More
Aerami Therapeutics, formerly known as Dance Biopharm Holdings Inc., has raised $4.6 million in equity, according to a securities filing.
Read More
